Cogent Biosciences (COGT) Cash from Operations (2017 - 2026)

Cogent Biosciences' Cash from Operations history runs 10 years deep, the most recent figure standing at 86883000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 30.63% year-over-year to 86883000.0; the TTM figure through Mar 2026 stood at 284816000.0 (down 28.43% YoY), while the FY2025 annual figure was 264444000.0, down 27.26% from the prior year.
• Cash from Operations was 86883000.0 for Q1 2026 at Cogent Biosciences, down from 79105000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 26456000.0 in Q2 2022 to a low of 86883000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 48904705.88 across 5 years, with a median of 44070000.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations sank 149.29% in 2022, then dropped 10.25% in 2023.
• A 5-year view of Cash from Operations shows it stood at 29408000.0 in 2022, then sank by 49.86% to 44070000.0 in 2023, then plunged by 37.46% to 60577000.0 in 2024, then tumbled by 30.59% to 79105000.0 in 2025, then dropped by 9.83% to 86883000.0 in 2026.
• The last three Cash from Operations figures came in at 86883000.0 (Q1 2026), 79105000.0 (Q4 2025), and 64286000.0 (Q3 2025), per Business Quant data.